May 30, 2025 02:46 PM EDT

AstraZeneca agrees to pay $51M to settle ‘pay-for-delay’ class action suit

Nicole DeFeudis

Editor

AstraZeneca and Handa Pharmaceuticals have agreed to pay a combined $51.4 million to resolve a class action lawsuit that claimed they unlawfully delayed the availability …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AstraZeneca agrees to pay $51M to settle ‘pay-for-delay’ class action suit

Nicole DeFeudis

Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Omada Health is going public on Friday at a $1.1B valuation

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

FDA's Makary looks at ways to speed drug approvals, talks about cutting user fees

Trump's health appointees pledge support for cell and gene therapies at FDA roundtable

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

As­traZeneca agrees to pay $51M to set­tle ‘pay-for-de­lay’ class ac­tion suit

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

AstraZeneca agrees to pay $51M to settle ‘pay-for-delay’ class action suit